Advertisement

Clinical Drug Investigation

, Volume 12, Issue 3, pp 127–134 | Cite as

Postmarketing Surveillance of Perindopril in Australia

  • Trefor Morgan
Clinical Use
  • 5 Downloads

Summary

Perindopril was released on the Australian market in 1992 and was the third angiotensin converting enzyme (ACE) inhibitor to be marketed in this country. A general practice postmarketing surveillance study was undertaken for 12 months in 1191 patients who were prescribed Perindopril to treat hypertension or cardiac failure. Clinical improvement was reported in approximately 80% of patients and this continued throughout the study in 70%. The drug was well tolerated and its adverse effect profile was similar to that of other ACE inhibitors, with cough as the principal effect. Hypotension was uncommon and occurred in only 4 patients. 45 patients were hospitalised during the study primarily because of cardiovascular events. 11 patients died during the study, and 7 of these were more than 80 years of age. In conclusion, Perindopril was an effective, well tolerated drug when used in general practice to treat hypertension and cardiac failure.

Keywords

Adis International Limited Angiotensin Converting Enzyme Captopril Enalapril Angiotensin Converting Enzyme Inhibitor 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Fletcher AR Spontaneous adverse drug reaction reporting vs event monitoring: a comparison. J Royal Soc Med 1991; 84: 341–4Google Scholar
  2. 2.
    Fletcher AP, Griffin JR International monitoring for adverse drug reactions of long latency. Adverse Drug React Toxicol Rev 1991; 10(4): 209–30PubMedGoogle Scholar
  3. 3.
    Kurowski M. The SPALA Project — an intensive monitoring system for non-steroidal anti-inflammatory drugs. In: Kurowski M, editor. Clinical Pharmacoepidemiology [data on file]Google Scholar
  4. 4.
    Anderson A, Morgan O, Morgan TO. Effectiveness of blood pressure control with once daily administration of enalapril and Perindopril. Am J Hypertens 1994; 7: 371–3PubMedGoogle Scholar
  5. 5.
    Thurston A, Mimran A, Zanchetti A, et al. A double blind comparison of Perindopril and atenolol in essential hypertension. J Human Hypertens 1990; 4: 547–52Google Scholar
  6. 6.
    Lees KR, Reid JL, Scott MGB, et al. Captopril versus Perindopril: a double blind study in essential hypertension. J Human Hypertens 1989; 3: 17–22Google Scholar
  7. 7.
    Morgan TO and Australian Multicentre Study Group. Australian Multicentre Study of Perindopril compared with atenolol in the management of hypertension. JAMA SEA 1990; 6 Suppl. (12): 18–22Google Scholar

Copyright information

© Adis International Limited 1996

Authors and Affiliations

  • Trefor Morgan
    • 1
  1. 1.Department of PhysiologyUniversity of MelbourneParkvilleAustralia

Personalised recommendations